z-logo
open-access-imgOpen Access
Everolimus for the treatment of epithelioid hemangioma: a case report
Author(s) -
Mururul Aisyi,
Ayu Hutami Syarif,
Dewi Aisyah Mukarramah,
Rio Hermawan,
Dewi Iriani
Publication year - 2021
Publication title -
medical journal of indonesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.164
H-Index - 9
eISSN - 2252-8083
pISSN - 0853-1773
DOI - 10.13181/mji.cr.205036
Subject(s) - medicine , everolimus , sclerotherapy , hemangioma , lesion , radiology , surgery
Epithelioid hemangioma is a rare benign vascular tumor manifested as slow-growing subcutaneous or dermal nodules. A previously therapeutic strategy involved surgical excision and sclerotherapy. However, no standard treatment has been established. Here, we reported an atypical case of epithelioid hemangioma that had a locally aggressive behavior and was successfully treated with everolimus, a rapamycin analog used for cancer therapy. A 1-year-old boy presented with an ulcerated lump in the left palmar region. The imaging test results, confirmed through histopathologic examination, suggested a diagnosis of epithelioid hemangioma. Targeted therapy with everolimus was administered orally because of a minimal response to initial transarterial sclerotherapy. The patient achieved a satisfactory response with a significantly reduced lesion size and improved hand function after a 2-year follow-up. This finding showed that patients with locally aggressive forms of epithelioid hemangioma may significantly benefit from everolimus as a potential targeted therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom